Almirall

(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 8th to 11th, 2024. Carlos Gallardo, Chairman and CEO … Read the full press release →

(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release →

(IN BRIEF) Almirall, a global biopharmaceutical company specializing in medical dermatology, has entered into an agreement with Centrient Pharmaceuticals, a leader in sustainable biosynthetic pharmaceuticals, to establish a dedicated innovation lab at Almirall’s R&D center in Sant Feliu de Llobregat, … Read the full press release →